[Pharma-clinics. Drug of the month. Zaleplon (Sonata)]

Rev Med Liege. 1999 Aug;54(8):705-6.
[Article in French]

Abstract

Zaleplon (Sonata) is an original hypnotic derived from the pyrazolopyrimidine with a full agonistic activity on central benzodiazepine receptors B21 type. Zaleplon is characterized by an extremely short half-life (about 1 hour). At the 10 mg dose, it is an affective sleep inducer with limited risks of disturbances in morning performance. It is particularly suitable for the treatment of initial insomnia when the prescription of an hypnotic is justified.

MeSH terms

  • Acetamides / pharmacokinetics
  • Acetamides / pharmacology
  • Acetamides / therapeutic use*
  • Dose-Response Relationship, Drug
  • Half-Life
  • Humans
  • Hypnotics and Sedatives / pharmacokinetics
  • Hypnotics and Sedatives / pharmacology
  • Hypnotics and Sedatives / therapeutic use*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Sleep Initiation and Maintenance Disorders / drug therapy*

Substances

  • Acetamides
  • Hypnotics and Sedatives
  • Pyrimidines
  • zaleplon